Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T60693
|
||||
Former ID |
TTDS00127
|
||||
Target Name |
Kappa-type opioid receptor
|
||||
Gene Name |
OPRK1
|
||||
Synonyms |
KOR; KOR-1; Kappa opioid receptor; Opioid receptor Kappa; OPRK1
|
||||
Target Type |
Successful
|
||||
Disease | Alcohol use disorders [ICD9: 303; ICD10: F10.2] | ||||
Bipolar disorder [ICD9: 296.0, 296.1, 296.4, 296.5, 296.6, 296.7, 296.8, 300; ICD10: F31, F40-F42] | |||||
Coronary artery restenosis; Multiple myeloma [ICD9:203; ICD10: I51.89, C90] | |||||
Diarrhea-predominant IBS [ICD9: 564.1; ICD10: K58.0] | |||||
Erythema [ICD9: 695; ICD10: L51-L54] | |||||
Inflammatory bowel disease [ICD9: 555, 556; ICD10: K50, K51] | |||||
Neurodegenerative disease [ICD9: 330-337; ICD10: G30-G32] | |||||
Opiate dependence [ICD9: 304; ICD10: F11] | |||||
Obesity [ICD9: 278; ICD10: E66] | |||||
Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89] | |||||
Substance dependence [ICD10: F10-F19] | |||||
Unspecified [ICD code not available] | |||||
Function |
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids.May play a role in arousal and regulation of autonomic and neuroendocrine functions.
|
||||
BioChemical Class |
GPCR rhodopsin
|
||||
Target Validation |
T60693
|
||||
UniProt ID | |||||
Sequence |
MDSPIQIFRGEPGPTCAPSACLPPNSSAWFPGWAEPDSNGSAGSEDAQLEPAHISPAIPV
IITAVYSVVFVVGLVGNSLVMFVIIRYTKMKTATNIYIFNLALADALVTTTMPFQSTVYL MNSWPFGDVLCKIVISIDYYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPLKAKIINI CIWLLSSSVGISAIVLGGTKVREDVDVIECSLQFPDDDYSWWDLFMKICVFIFAFVIPVL IIIVCYTLMILRLKSVRLLSGSREKDRNLRRITRLVLVVVAVFVVCWTPIHIFILVEALG STSHSTAALSSYYFCIALGYTNSSLNPILYAFLDENFKRCFRDFCFPLKMRMERQSTSRV RNTVQDPAYLRDIDGMNKPV |
||||
Drugs and Mode of Action | |||||
Drug(s) | CHLOROXINE | Drug Info | Approved | Erythema | [551871] |
Dezocine | Drug Info | Approved | Pain | [536361] | |
Nalbuphine | Drug Info | Approved | Pain | [538227], [539027] | |
Rapamycin | Drug Info | Approved | Coronary artery restenosis; Multiple myeloma | [545206], [551871] | |
Asimadoline | Drug Info | Phase 3 | Diarrhea-predominant IBS | [536224] | |
Nalbuphine hydrochloride ER | Drug Info | Phase 3 | Pain | [521828] | |
TRK-820 | Drug Info | Phase 3 | Discovery agent | [523764] | |
CR-845 iv infusion | Drug Info | Phase 2/3 | Pain | [525310] | |
PHN-131 | Drug Info | Phase 2/3 | Pain | [548815] | |
Apadoline | Drug Info | Phase 2 | Pain | [527613] | |
Carfentanil | Drug Info | Phase 2 | Discovery agent | [524366] | |
CR-665 | Drug Info | Phase 2 | Pain | [529725] | |
Enadoline | Drug Info | Phase 2 | Pain | [525469], [539017] | |
MAL formulation | Drug Info | Phase 2 | Opiate dependence | [550591] | |
Niravoline | Drug Info | Phase 2 | Pain | [545439] | |
TPM-1/Morphine | Drug Info | Phase 2 | Pain | [548201] | |
BRL-52656 | Drug Info | Phase 1 | Pain | [534016] | |
LY-2456302 | Drug Info | Phase 1 | Alcohol use disorders | [524877] | |
MCP-201 | Drug Info | Phase 1 | Pain | [547634] | |
PF-4455242 | Drug Info | Phase 1 | Bipolar disorder | [522809] | |
GNTI | Drug Info | Preclinical | Obesity | [536122] | |
CLIOQUINOL | Drug Info | Withdrawn from market | Discovery agent | [522766] | |
ADL 10-0101 | Drug Info | Discontinued in Phase 2 | Pain | [546982] | |
DYNORPHIN A | Drug Info | Discontinued in Phase 2 | Discovery agent | [538995], [546012] | |
E-2078 | Drug Info | Discontinued in Phase 2 | Pain | [539019], [545374] | |
R-84760 | Drug Info | Discontinued in Phase 2 | Pain | [546014] | |
VP004 | Drug Info | Discontinued in Phase 1 | Substance dependence | [548458] | |
Fedotozine | Drug Info | Terminated | Discovery agent | [544798] | |
GR-89696 | Drug Info | Terminated | Neurodegenerative disease | [539020], [545442] | |
GR-94839 | Drug Info | Terminated | Pain | [545572] | |
KT-95 | Drug Info | Terminated | Inflammatory bowel disease | [546410] | |
LY-255582 | Drug Info | Terminated | Discovery agent | [545880] | |
SB-213698 | Drug Info | Terminated | Discovery agent | [546084] | |
Inhibitor | (-)-cyclorphan | Drug Info | [527951] | ||
1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol | Drug Info | [528785] | |||
1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol | Drug Info | [528785] | |||
1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol | Drug Info | [528785] | |||
1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine | Drug Info | [528785] | |||
1-benzhydryl-4-(furan-2-yl)piperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-benzylpiperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-butylpiperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-cyclohexylpiperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-ethoxy-4-phenylpiperidine | Drug Info | [528785] | |||
1-benzhydryl-4-hexylpiperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-isopropylpiperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-m-tolylpiperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-methoxy-4-phenylpiperidine | Drug Info | [528785] | |||
1-benzhydryl-4-o-tolylpiperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-p-tolylpiperidin-4-ol | Drug Info | [528781] | |||
1-benzhydryl-4-phenyl-4-propoxypiperidine | Drug Info | [528785] | |||
1-benzhydryl-4-phenylpiperidin-4-ol | Drug Info | [530052] | |||
1-benzhydryl-4-tert-butylpiperidin-4-ol | Drug Info | [528781] | |||
12-EPI-SALVINORIN A | Drug Info | [529925] | |||
14-O-phenylpropylnaltrexone | Drug Info | [529991] | |||
17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine | Drug Info | [530529] | |||
17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine | Drug Info | [530529] | |||
17-methyl-4'-methyldihydromorphinone | Drug Info | [528375] | |||
17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate | Drug Info | [530529] | |||
2-(2-methylquinolin-4-ylamino)-N-phenylacetamide | Drug Info | [530283] | |||
2-Benzylaminomethyl-3-hydroxymorphinan | Drug Info | [530529] | |||
2-EPI-2-THIOSALVINORIN A | Drug Info | [528678] | |||
2-EPI-2-THIOSALVINORIN B | Drug Info | [528678] | |||
2-Hydroxymethyl-3-hydroxymorphinan | Drug Info | [530529] | |||
2-THIOSALVINORIN B | Drug Info | [528678] | |||
3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole | Drug Info | [528151] | |||
3-(1-benzylpiperidin-4-yloxy)benzamide | Drug Info | [531117] | |||
3-desoxy-3-carboxamidonaltrexone | Drug Info | [530013] | |||
4-(4-((phenethylamino)methyl)phenoxy)benzamide | Drug Info | [528996] | |||
4-(p-Tolyl)spiro[chromene-2,4'-piperidine] | Drug Info | [529689] | |||
4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide | Drug Info | [530324] | |||
4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol | Drug Info | [529689] | |||
4-phenyl-1-(1-phenylbutyl)piperidin-4-ol | Drug Info | [528785] | |||
4-phenyl-1-(1-phenylethyl)piperidin-4-ol | Drug Info | [528785] | |||
4-phenyl-1-(1-phenylheptyl)piperidin-4-ol | Drug Info | [528785] | |||
4-phenyl-1-(1-phenylhexyl)piperidin-4-ol | Drug Info | [528785] | |||
4-phenyl-1-(1-phenylpentyl)piperidin-4-ol | Drug Info | [528785] | |||
4-phenyl-1-(1-phenylpropyl)piperidin-4-ol | Drug Info | [528785] | |||
4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol | Drug Info | [528785] | |||
4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol | Drug Info | [528785] | |||
4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol | Drug Info | [528785] | |||
4-phenyl-4-[1H-imidazol-2-yl]-piperidine | Drug Info | [527810] | |||
4-Phenylspiro[chromene-2,4'-piperidine] | Drug Info | [529689] | |||
5-(4-((phenethylamino)methyl)phenoxy)picolinamide | Drug Info | [528996] | |||
6-(4-((benzylamino)methyl)phenoxy)nicotinamide | Drug Info | [528996] | |||
6-(4-((phenethylamino)methyl)phenoxy)nicotinamide | Drug Info | [529132] | |||
6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide | Drug Info | [529132] | |||
6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide | Drug Info | [528996] | |||
6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol | Drug Info | [533539] | |||
6-desoxonaltrexone | Drug Info | [530013] | |||
6beta-naltrexol HCl | Drug Info | [530077] | |||
8-azabicyclo[3.2.1]octan-3-yloxy-benzamide | Drug Info | [531109] | |||
8-carboxamidocyclazocine | Drug Info | [529429] | |||
ANISOCOUMARIN H | Drug Info | [529238] | |||
Benzyl derivative of M6G | Drug Info | [527461] | |||
Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate | Drug Info | [527951] | |||
BUTORPHAN | Drug Info | [525672] | |||
CCDC 710249, HCl salt | Drug Info | [530013] | |||
CHLOROXINE | Drug Info | [531262] | |||
Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH | Drug Info | [528875] | |||
CLIOQUINOL | Drug Info | [531262] | |||
Clocinnamox | Drug Info | [529991] | |||
CYCLAZOCINE | Drug Info | [525672] | |||
CYCLORPHAN | Drug Info | [525672] | |||
C[L-Ala-D-pro-L-Phe-D-trp] | Drug Info | [530160] | |||
C[L-mTyr-D-pro-L-Phe-D-trp] | Drug Info | [530160] | |||
C[L-Phe-D-pro-L-mTyr-D-trp] | Drug Info | [530160] | |||
C[L-Phe-D-pro-L-Phe-D-trp] | Drug Info | [530160] | |||
C[L-Phe-D-pro-L-Phe-L-trp] | Drug Info | [530160] | |||
C[L-Phe-D-pro-L-Tyr(OMe)-D-trp] | Drug Info | [530160] | |||
C[L-Phe-D-pro-L-Tyr-D-trp] | Drug Info | [530160] | |||
C[L-Tyr(OMe)-D-pro-L-Phe-D-trp] | Drug Info | [530160] | |||
C[L-Tyr-D-pro-L-Phe-D-trp] | Drug Info | [530160] | |||
DAMGO | Drug Info | [528255] | |||
Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2 | Drug Info | [528376] | |||
Delta-kappa opioid heterodimer | Drug Info | [527089] | |||
DEOXY SALVINORIN A | Drug Info | [528254] | |||
Deprotected cogener of M6G | Drug Info | [527461] | |||
Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2 | Drug Info | [528376] | |||
Dimepheptanol | Drug Info | [533539] | |||
DM6S | Drug Info | [528255] | |||
Dmt-Pro-3,5Dmp-Phe-NH2 | Drug Info | [528832] | |||
Dmt-Pro-Dmp-Phe-NH2 | Drug Info | [528832] | |||
Dmt-Pro-Dmt-Phe-NH2 | Drug Info | [528832] | |||
Dmt-Pro-Emp-Phe-NH2 | Drug Info | [528832] | |||
Dmt-Pro-Imp-Phe-NH2 | Drug Info | [528832] | |||
Dmt-Pro-Mmp-Phe-NH2 | Drug Info | [528832] | |||
Dmt-Pro-Phe-Phe-NH2 | Drug Info | [528832] | |||
Dmt-Pro-Tmp-Phe-NH2 | Drug Info | [528832] | |||
DPDPE | Drug Info | [526762] | |||
DYNORPHIN A | Drug Info | [529478] | |||
Dynorphin(1-8) | Drug Info | [533377] | |||
ELAEOCARPENINE | Drug Info | [530705] | |||
ENDOMORPHIN 2 | Drug Info | [526937] | |||
ENDOMORPHIN-1 | Drug Info | [526937] | |||
ETONITAZENE | Drug Info | [531519] | |||
FALCARINDIOL | Drug Info | [529238] | |||
H-Cdp-ala-Gly-Phe-leu-OH | Drug Info | [528724] | |||
H-Cdp-Gly-Gly-Phe-Leu-OH | Drug Info | [528724] | |||
H-Cpa-Gly-Gly-Phe-Met-NH2 | Drug Info | [528724] | |||
H-Cpa-Gly-Gly-Phe-Met-OH | Drug Info | [528724] | |||
H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH | Drug Info | [528875] | |||
H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2 | Drug Info | [528692] | |||
H-Tyr-c[D-Allylgly-Gly-Phe-L-Allylgly]NH2 | Drug Info | [528692] | |||
H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2 | Drug Info | [528692] | |||
H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2 | Drug Info | [528692] | |||
H-Tyr-Gly-Gly-Phe-Met-NH2 | Drug Info | [528724] | |||
HERKINORIN | Drug Info | [529401] | |||
HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2 | Drug Info | [530428] | |||
ICI-199441 | Drug Info | [534134] | |||
KETOCYCLAZOCINE | Drug Info | [529816] | |||
KNT-62 | Drug Info | [530556] | |||
KNT-63 | Drug Info | [530556] | |||
LOFENTANIL | Drug Info | [533543] | |||
LY-255582 | Drug Info | [534631] | |||
M3A6S | Drug Info | [528255] | |||
M3IBu6S | Drug Info | [528255] | |||
M3P6S | Drug Info | [528255] | |||
M3Pr6S | Drug Info | [528255] | |||
M6G thiosaccharide analogue | Drug Info | [527461] | |||
M6S | Drug Info | [528255] | |||
MC-CAM | Drug Info | [530461] | |||
MCL-117 | Drug Info | [527951] | |||
MCL-139 | Drug Info | [527951] | |||
MCL-144 | Drug Info | [530279] | |||
MCL-145 | Drug Info | [527951] | |||
MCL-147 | Drug Info | [528787] | |||
MCL-149 | Drug Info | [528787] | |||
MCL-153 | Drug Info | [530707] | |||
MCL-154 | Drug Info | [530707] | |||
MCL-182 | Drug Info | [528787] | |||
MCL-183 | Drug Info | [528787] | |||
MCL-428 | Drug Info | [528655] | |||
MCL-429 | Drug Info | [528655] | |||
MCL-431 | Drug Info | [528655] | |||
MCL-432 | Drug Info | [528655] | |||
MCL-433 | Drug Info | [528655] | |||
MCL-434 | Drug Info | [528655] | |||
MCL-435 | Drug Info | [528655] | |||
MCL-443 | Drug Info | [528655] | |||
MCL-444 | Drug Info | [528655] | |||
MCL-445 | Drug Info | [528787] | |||
MCL-446 | Drug Info | [528787] | |||
MCL-447 | Drug Info | [528787] | |||
MCL-448 | Drug Info | [528787] | |||
MCL-449 | Drug Info | [528655] | |||
MCL-450 | Drug Info | [528412] | |||
MCL-451 | Drug Info | [528412] | |||
MCL-457 | Drug Info | [528787] | |||
MCL-458 | Drug Info | [528787] | |||
METAZOCINE | Drug Info | [529816] | |||
MK-1925 | Drug Info | [530242] | |||
Morphinan Cyclic Imine analogue | Drug Info | [551291] | |||
MR-1029 | Drug Info | [528070] | |||
MR-1526 | Drug Info | [528070] | |||
MR-2034 | Drug Info | [529816] | |||
MR-2266 | Drug Info | [528070] | |||
N,N-diallyl[D-Pro-10]Dyn A-(1-11) | Drug Info | [534450] | |||
N,N-dibenzyl[D-Pro-10]Dyn A-(1-11) | Drug Info | [534450] | |||
N,N-diCPM[D-Pro-10]Dyn A-(1-11) | Drug Info | [534450] | |||
N-(17-Methylmorphinan-3-yl)-N'-phenylurea | Drug Info | [530529] | |||
N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea | Drug Info | [530529] | |||
N-allyl[D-Pro-10]Dyn A-(1-11) | Drug Info | [534450] | |||
N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine | Drug Info | [530529] | |||
N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine | Drug Info | [530529] | |||
N-benzyl[D-Pro-10]Dyn A-(1-11) | Drug Info | [534450] | |||
N-CPM[D-Pro-10]Dyn A-(1-11) | Drug Info | [534450] | |||
N-isobutylnoroxymorphone | Drug Info | [529662] | |||
NalBzOH | Drug Info | [528255] | |||
Naltrexone-6-alpha-ol | Drug Info | [529816] | |||
Naltrexone-6-beta-ol | Drug Info | [529816] | |||
NORBINALTORPHIMINE | Drug Info | [531086] | |||
Norbinaltorphimine derivative | Drug Info | [527459] | |||
O-DESMETHYL TRAMADOL | Drug Info | [529816] | |||
OXYMORPHINDOLE | Drug Info | [529414] | |||
Oxymorphone semicarbazone hydrochloride | Drug Info | [533377] | |||
PHENAZOCINE | Drug Info | [529816] | |||
RTI-5989-23 | Drug Info | [534631] | |||
RTI-5989-25 | Drug Info | [534631] | |||
RTI-5989-31 | Drug Info | [528947] | |||
Salvinicin A | Drug Info | [528906] | |||
SALVINICIN B | Drug Info | [528906] | |||
SALVINORIN A | Drug Info | [529331] | |||
Salvinorin A (ester) | Drug Info | [528254] | |||
SALVINORIN B | Drug Info | [529401] | |||
Salvinorin B 1-ethoxyethyl ether | Drug Info | [529133] | |||
Salvinorin B 2,2,2-trifluoroethoxymethyl ether | Drug Info | [529133] | |||
Salvinorin B 2-fluoroethoxymethyl ether | Drug Info | [529133] | |||
Salvinorin B 2-methoxy-2-propyl ether | Drug Info | [529133] | |||
Salvinorin B 2-methoxyethoxymethyl ether | Drug Info | [529133] | |||
Salvinorin B benzyloxymethyl ether | Drug Info | [529133] | |||
Salvinorin B butoxymethyl ether | Drug Info | [529133] | |||
Salvinorin B ethoxymethyl ether | Drug Info | [529133] | |||
Salvinorin B fluoromethyl ether | Drug Info | [529133] | |||
Salvinorin B isopropoxymethyl ether | Drug Info | [529133] | |||
Salvinorin B methoxymethyl ether | Drug Info | [529133] | |||
Salvinorin B methylthiomethyl ether | Drug Info | [529133] | |||
Salvinorin B propoxymethyl ether | Drug Info | [529133] | |||
Salvinorin B tert-butoxymethyl ether | Drug Info | [529133] | |||
Salvinorin B tetrahydropyran-2-yl ether | Drug Info | [529133] | |||
SB-213698 | Drug Info | [530073] | |||
SN-11 | Drug Info | [530073] | |||
SN-23 | Drug Info | [530073] | |||
SN-28 | Drug Info | [531165] | |||
SPIROINDANYLOXYMORPHONE | Drug Info | [530268] | |||
TPM-1/Morphine | Drug Info | [544320] | |||
Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH | Drug Info | [528875] | |||
TRK-820 | Drug Info | [530556] | |||
U-69593 | Drug Info | [530889] | |||
ZYKLOPHIN | Drug Info | [530428] | |||
[Dcp1]Dyn A(1-11)-NH2 | Drug Info | [528376] | |||
[Leu5]enkephalin | Drug Info | [530780] | |||
Agonist | 3-Methylfentanyl | Drug Info | [551402] | ||
3-Methylthiofentanyl | Drug Info | [551408] | |||
ADL 10-0101 | Drug Info | [526497] | |||
Apadoline | Drug Info | [527613] | |||
Asimadoline | Drug Info | [536224] | |||
BRL 52537 hydrochloride | Drug Info | [535870] | |||
BRL 52974 | Drug Info | [534953] | |||
BRL-52656 | Drug Info | [525670] | |||
Carfentanil | Drug Info | [551406] | |||
CR-665 | Drug Info | [530309] | |||
CR-845 iv infusion | Drug Info | [544079] | |||
Dihydromorphine | Drug Info | [551379] | |||
dynorphin B | Drug Info | [534018] | |||
Enadoline | Drug Info | [525469] | |||
ethyketazocine | Drug Info | [534443] | |||
ethylketocyclazocine | Drug Info | [543763] | |||
Fedotozine | Drug Info | [535539] | |||
MAL formulation | Drug Info | [550590] | |||
MCP-201 | Drug Info | [550920] | |||
Nalorphine | Drug Info | [534939] | |||
normorphine | Drug Info | [543763] | |||
NRP290 | Drug Info | [543763] | |||
PHN-131 | Drug Info | [533353] | |||
R-84760 | Drug Info | [534614] | |||
spiradoline | Drug Info | [534018] | |||
tifluadom | Drug Info | [534443] | |||
U50,488H | Drug Info | [534904], [535113] | |||
[3H]enadoline | Drug Info | [525997] | |||
[3H]U69593 | Drug Info | [533399] | |||
Antagonist | 5'-guanidinonaltrindole | Drug Info | [525829] | ||
Beta-endorphin | Drug Info | [537931] | |||
Dezocine | Drug Info | [536176] | |||
Diprenorphine | Drug Info | [551387] | |||
Drug 7684380 | Drug Info | [537853] | |||
GNTI | Drug Info | [536122] | |||
L-685,818 | Drug Info | [537853] | |||
LY-2456302 | Drug Info | [532492] | |||
naltriben | Drug Info | [543763] | |||
Nor-binaltorphimine dihydrochloride | Drug Info | [535870] | |||
quadazocine | Drug Info | [543763] | |||
Rapamycin | Drug Info | [538126] | |||
[3H]diprenorphine | Drug Info | [533664] | |||
[U-13C]ascomycin | Drug Info | [535822] | |||
Modulator | E-2078 | Drug Info | [525491] | ||
GR-38414 | Drug Info | ||||
GR-45809 | Drug Info | ||||
GR-86014 | Drug Info | ||||
GR-89696 | Drug Info | [526244] | |||
GR-91272 | Drug Info | ||||
GR-94839 | Drug Info | [526749] | |||
ICI-204448 | Drug Info | ||||
KT-95 | Drug Info | [543763] | |||
Nalbuphine | Drug Info | [556264] | |||
Nalbuphine hydrochloride ER | Drug Info | ||||
Niravoline | Drug Info | ||||
PF-4455242 | Drug Info | [531552] | |||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
Opioid prodynorphin pathway | |||||
Reactome | Peptide ligand-binding receptors | ||||
G alpha (i) signalling events | |||||
WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
Peptide GPCRs | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
Ref 521828 | ClinicalTrials.gov (NCT00323154) Nalbuphine for the Treatment of Opioid Induced Pruritus in Children. U.S. National Institutes of Health. | ||||
Ref 522766 | ClinicalTrials.gov (NCT00963495) Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy. U.S. National Institutes of Health. | ||||
Ref 522809 | ClinicalTrials.gov (NCT00988949) Proof Of Mechanism Study To Determine Efficacy Of PF-04455242 In Blocking Spiradoline (PF-00345768) Stimulated Prolactin Release. U.S. National Institutes of Health. | ||||
Ref 523764 | ClinicalTrials.gov (NCT01513161) Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis. U.S. National Institutes of Health. | ||||
Ref 524366 | ClinicalTrials.gov (NCT01899170) Towards Individualized Deep Brain Stimulation Treatment of Chronic Neuropathic Pain. U.S. National Institutes of Health. | ||||
Ref 524877 | ClinicalTrials.gov (NCT02218775) FASTMAS (New Experimental Medicine Studies: Fast-Fail Trials in Mood and Anxiety Spectrum Disorders) Kappa Opioid Receptor (KOR) Phase 1 Study. U.S. National Institutes of Health. | ||||
Ref 525310 | ClinicalTrials.gov (NCT02542384) A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery. | ||||
Ref 525469 | Enadoline, a selective kappa-opioid receptor agonist shows potent antihyperalgesic and antiallodynic actions in a rat model of surgical pain. Pain. 1999 Mar;80(1-2):383-9. | ||||
Ref 527613 | Novel developments with selective, non-peptidic kappa-opioid receptor agonists. Expert Opin Investig Drugs. 1997 Oct;6(10):1351-68. | ||||
Ref 529725 | Effect of a kappa-opioid agonist, i.v. JNJ-38488502, on sensation of colonic distensions in healthy male volunteers. Neurogastroenterol Motil. 2009 Mar;21(3):281-90. | ||||
Ref 534016 | Opiate receptors within the blood-brain barrier mediate kappa agonist-induced water diuresis. J Pharmacol Exp Ther. 1993 Jul;266(1):164-71. | ||||
Ref 536122 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | ||||
Ref 536224 | Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. | ||||
Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
Ref 538227 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 070692. | ||||
Ref 538995 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1620). | ||||
Ref 539017 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1646). | ||||
Ref 539019 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1648). | ||||
Ref 539020 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1649). | ||||
Ref 539027 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1663). | ||||
Ref 544798 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001140) | ||||
Ref 545206 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002452) | ||||
Ref 545374 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003061) | ||||
Ref 545439 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003260) | ||||
Ref 545442 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003263) | ||||
Ref 545572 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003733) | ||||
Ref 545880 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005187) | ||||
Ref 546012 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005877) | ||||
Ref 546014 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005881) | ||||
Ref 546084 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006271) | ||||
Ref 546410 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007966) | ||||
Ref 546982 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011770) | ||||
Ref 547634 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018011) | ||||
Ref 548201 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023017) | ||||
Ref 548458 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025668) | ||||
Ref 525469 | Enadoline, a selective kappa-opioid receptor agonist shows potent antihyperalgesic and antiallodynic actions in a rat model of surgical pain. Pain. 1999 Mar;80(1-2):383-9. | ||||
Ref 525491 | Systemic effects of E-2078, a stabilized dynorphin A(1-8) analog, in rhesus monkeys. Psychopharmacology (Berl). 1999 Apr;143(2):190-6. | ||||
Ref 525670 | Kappa-opioid receptors behind the blood-brain barrier are involved in the anti-hypertensive effects of systemically administered kappa-agonists in the conscious spontaneously hypertensive rat. J Pharm Pharmacol. 1999 Nov;51(11):1251-6. | ||||
Ref 525672 | J Med Chem. 2000 Jan 13;43(1):114-22.Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence. | ||||
Ref 525829 | Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. J Med Chem. 2000 Jul 13;43(14):2759-69. | ||||
Ref 525997 | Analysis of [3H]bremazocine binding in single and combinatorial opioid receptor knockout mice. Eur J Pharmacol. 2001 Mar 2;414(2-3):189-95. | ||||
Ref 526244 | [(11)C]-GR89696, a potent kappa opiate receptor radioligand; in vivo binding of the R and S enantiomers. Nucl Med Biol. 2002 Jan;29(1):47-53. | ||||
Ref 526497 | Analgesia from a peripherally active kappa-opioid receptor agonist in patients with chronic pancreatitis. Pain. 2003 Jan;101(1-2):89-95. | ||||
Ref 526749 | GR94839, a kappa-opioid agonist with limited access to the central nervous system, has antinociceptive activity. Br J Pharmacol. 1992 Aug;106(4):783-9. | ||||
Ref 526762 | J Med Chem. 1992 Nov 13;35(23):4325-9.Opioid agonist and antagonist activities of morphindoles related to naltrindole. | ||||
Ref 526937 | J Med Chem. 2004 Jan 29;47(3):735-43.Structure-activity study on the Phe side chain arrangement of endomorphins using conformationally constrained analogues. | ||||
Ref 527089 | J Med Chem. 2004 Jun 3;47(12):2969-72.A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers. | ||||
Ref 527459 | J Med Chem. 2005 Mar 10;48(5):1676-9.Major effect of pyrrolic N-benzylation in norbinaltorphimine, the selective kappa-opioid receptor antagonist. | ||||
Ref 527461 | Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6.Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. | ||||
Ref 527613 | Novel developments with selective, non-peptidic kappa-opioid receptor agonists. Expert Opin Investig Drugs. 1997 Oct;6(10):1351-68. | ||||
Ref 527810 | Bioorg Med Chem Lett. 2006 Jan 1;16(1):146-9. Epub 2005 Oct 19.4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives, a novel class of selective delta-opioid agonists. | ||||
Ref 527951 | J Med Chem. 2006 Jan 12;49(1):256-62.Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors. | ||||
Ref 528070 | J Med Chem. 1991 Aug;34(8):2438-44.Electrophilic gamma-lactone kappa-opioid receptor probes. Analogues of 2'-hydroxy-2-tetrahydrofurfuryl-5,9-dimethyl-6,7-benzomorphan diastereomers. | ||||
Ref 528151 | Bioorg Med Chem Lett. 2006 Jul 1;16(13):3524-8. Epub 2006 Apr 24.3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2,3-b]pyridines as ligands for the ORL-1 receptor. | ||||
Ref 528254 | Bioorg Med Chem Lett. 2006 Sep 1;16(17):4679-85. Epub 2006 Jun 13.Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18). | ||||
Ref 528255 | Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. | ||||
Ref 528375 | J Med Chem. 2006 Aug 24;49(17):5333-8.Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones. | ||||
Ref 528376 | J Med Chem. 2006 Aug 24;49(17):5382-5.Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opioid antagonists. | ||||
Ref 528412 | J Med Chem. 2006 Sep 7;49(18):5640-3.New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. | ||||
Ref 528655 | Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. Epub 2007 Jan 17.High-affinity carbamate analogues of morphinan at opioid receptors. | ||||
Ref 528678 | Bioorg Med Chem Lett. 2007 Apr 15;17(8):2229-32. Epub 2007 Feb 2.Convenient synthesis and in vitro pharmacological activity of 2-thioanalogs of salvinorins A and B. | ||||
Ref 528692 | J Med Chem. 2007 Mar 22;50(6):1414-7. Epub 2007 Feb 22.Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. | ||||
Ref 528724 | Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. Epub 2007 Feb 2.Further studies of tyrosine surrogates in opioid receptor peptide ligands. | ||||
Ref 528781 | Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. | ||||
Ref 528785 | Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. | ||||
Ref 528787 | Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. Epub 2007 Mar 30.In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. | ||||
Ref 528832 | J Med Chem. 2007 Jun 14;50(12):2753-66. Epub 2007 May 12.Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands. | ||||
Ref 528875 | J Med Chem. 2007 Jun 28;50(13):3138-42. Epub 2007 Jun 1.Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. | ||||
Ref 528906 | J Med Chem. 2007 Jul 26;50(15):3596-603. Epub 2007 Jun 20.Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues. | ||||
Ref 528947 | J Med Chem. 2007 Aug 9;50(16):3765-76. Epub 2007 Jul 11.Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series. | ||||
Ref 528996 | Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. Epub 2007 Aug 11.Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. | ||||
Ref 529132 | Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6. Epub 2007 Oct 17.Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. | ||||
Ref 529133 | Bioorg Med Chem. 2008 Feb 1;16(3):1279-86. Epub 2007 Oct 24.Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. | ||||
Ref 529238 | Bioorg Med Chem. 2008 Mar 15;16(6):3218-23. Epub 2007 Dec 31.Novel coumarin glycoside and phenethyl vanillate from Notopterygium forbesii and their binding affinities for opioid and dopamine receptors. | ||||
Ref 529331 | J Med Chem. 2008 Mar 27;51(6):1824-30. Epub 2008 Feb 23.Toward a structure-based model of salvinorin A recognition of the kappa-opioid receptor. | ||||
Ref 529401 | J Med Chem. 2008 Apr 24;51(8):2421-31. Epub 2008 Apr 2.Herkinorin analogues with differential beta-arrestin-2 interactions. | ||||
Ref 529414 | Eur J Med Chem. 2008 Nov;43(11):2307-15. Epub 2008 Feb 29.Ligand binding to nucleic acids and proteins: Does selectivity increase with strength?. | ||||
Ref 529429 | Bioorg Med Chem. 2008 May 15;16(10):5653-64. Epub 2008 Mar 30.Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-carboxamidocyclazocine. | ||||
Ref 529478 | Bioorg Med Chem Lett. 2008 Jun 15;18(12):3667-71. Epub 2007 Dec 4.Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor. | ||||
Ref 529662 | Bioorg Med Chem Lett. 2008 Sep 15;18(18):4978-81. Epub 2008 Aug 12.Synthesis of N-isobutylnoroxymorphone from naltrexone by a selective cyclopropane ring opening reaction. | ||||
Ref 529689 | J Med Chem. 2008 Oct 9;51(19):5893-6. Epub 2008 Sep 13.Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859). | ||||
Ref 529816 | Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. Epub 2008 Nov 7.Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. | ||||
Ref 529925 | Bioorg Med Chem. 2009 Feb 1;17(3):1370-80. Epub 2008 Dec 14.Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor. | ||||
Ref 529991 | J Med Chem. 2009 Mar 26;52(6):1553-7.14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity. | ||||
Ref 530013 | Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94. Epub 2009 Feb 25.Syntheses of novel high affinity ligands for opioid receptors. | ||||
Ref 530052 | Bioorg Med Chem Lett. 2009 May 1;19(9):2519-23. Epub 2009 Mar 14.The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety. | ||||
Ref 530073 | Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5. Epub 2009 Mar 26.Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. | ||||
Ref 530077 | Bioorg Med Chem Lett. 2009 May 15;19(10):2811-4. Epub 2009 Mar 26.Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes. | ||||
Ref 530160 | Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. Epub 2009 May 3.Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. | ||||
Ref 530242 | Bioorg Med Chem Lett. 2009 Aug 15;19(16):4729-32. Epub 2009 Jun 17.Identification of MK-1925: a selective, orally active and brain-penetrable opioid receptor-like 1 (ORL1) antagonist. | ||||
Ref 530268 | Bioorg Med Chem. 2009 Aug 15;17(16):5983-8. Epub 2009 Jul 3.Aerobic oxidation of indolomorphinan without the 4,5-epoxy bridge and subsequent rearrangement of the oxidation product to spiroindolinonyl-C-normorphinan derivative. | ||||
Ref 530279 | J Med Chem. 2009 Dec 10;52(23):7389-96.Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands. | ||||
Ref 530283 | Bioorg Med Chem. 2009 Aug 15;17(16):5782-90. Epub 2009 Jul 18.Synthesis and characterizations of novel quinoline derivatives having mixed ligand activities at the kappa and mu receptors: Potential therapeutic efficacy against morphine dependence. | ||||
Ref 530309 | Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain. Anesthesiology. 2009 Sep;111(3):616-24. | ||||
Ref 530324 | J Med Chem. 2009 Sep 24;52(18):5685-702.Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747). | ||||
Ref 530428 | J Med Chem. 2009 Nov 12;52(21):6814-21.The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues. | ||||
Ref 530461 | J Med Chem. 2009 Nov 12;52(21):6926-30.14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid receptor antagonists. | ||||
Ref 530529 | J Med Chem. 2010 Jan 14;53(1):402-18.Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. | ||||
Ref 530556 | Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4. Epub 2009 Nov 13.Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. | ||||
Ref 530705 | Bioorg Med Chem Lett. 2010 Mar 1;20(5):1601-3. Epub 2010 Jan 22.Synthesis and evaluation of opioid receptor-binding affinity of elaeocarpenine and its analogs. | ||||
Ref 530707 | Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9. Epub 2010 Jan 25.Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. | ||||
Ref 530780 | J Med Chem. 2010 Apr 8;53(7):2875-81."Carba"-analogues of fentanyl are opioid receptor agonists. | ||||
Ref 530889 | J Med Chem. 2010 May 27;53(10):4212-22.Conformationally constrained kappa receptor agonists: stereoselective synthesis and pharmacological evaluation of 6,8-diazabicyclo[3.2.2]nonane derivatives. | ||||
Ref 531086 | Bioorg Med Chem Lett. 2010 Sep 1;20(17):5035-8. Epub 2010 Jul 13.Synthesis of pyrrolomorphinan derivatives as kappa opioid agonists. | ||||
Ref 531109 | Bioorg Med Chem Lett. 2010 Sep 15;20(18):5405-10. Epub 2010 Aug 3.SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2. | ||||
Ref 531117 | Bioorg Med Chem Lett. 2010 Oct 1;20(19):5847-52. Epub 2010 Jul 30.Discovery of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as selective antagonists of the kappa opioid receptor. Part 1. | ||||
Ref 531165 | Bioorg Med Chem Lett. 2010 Nov 1;20(21):6302-5. Epub 2010 Aug 21.Design and synthesis of KNT-127, a |A-opioid receptor agonist effective by systemic administration. | ||||
Ref 531262 | Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. Epub 2010 Oct 21.In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). | ||||
Ref 531519 | J Med Chem. 1990 Sep;33(9):2456-64.Photoactivatable opiate derivatives as irreversible probes of the mu-opioid receptor. | ||||
Ref 531552 | Design and discovery of a selective small molecule ? opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242). J Med Chem. 2011 Aug 25;54(16):5868-77. | ||||
Ref 532492 | LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology. 2014 Feb;77:131-44. | ||||
Ref 533353 | Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther. 1988 Jan;244(1):391-402. | ||||
Ref 533377 | J Med Chem. 1986 Jul;29(7):1222-5.Peptides as receptor selectivity modulators of opiate pharmacophores. | ||||
Ref 533399 | [3H]U-69593 a highly selective ligand for the opioid kappa receptor. Eur J Pharmacol. 1985 Feb 26;109(2):281-4. | ||||
Ref 533539 | J Med Chem. 1981 Jul;24(7):903-6.Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists. | ||||
Ref 533543 | J Med Chem. 1982 Aug;25(8):913-9.Potential affinity labels for the opiate receptor based on fentanyl and related compounds. | ||||
Ref 533664 | kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc Natl Acad Sci U S A.1995 Jul 18;92(15):7006-10. | ||||
Ref 534018 | Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6736-40. | ||||
Ref 534134 | J Med Chem. 1996 Apr 12;39(8):1729-35.Arylacetamide-derived fluorescent probes: synthesis, biological evaluation, and direct fluorescent labeling of kappa opioid receptors in mouse microglial cells. | ||||
Ref 534443 | Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands. J Pharmacol Exp Ther. 1997 Aug;282(2):676-84. | ||||
Ref 534450 | J Med Chem. 1997 Aug 15;40(17):2733-9.Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution. | ||||
Ref 534614 | Effects of R-84760, a selective kappa-opioid receptor agonist, on nociceptive reflex in isolated neonatal rat spinal cord. Eur J Pharmacol. 1998 Feb 19;343(2-3):171-7. | ||||
Ref 534631 | J Med Chem. 1998 May 21;41(11):1980-90.Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists. | ||||
Ref 534904 | Effects of kappa- and mu-opioid receptor agonists on Ca2+ channels in neuroblastoma cells: involvement of the orphan opioid receptor. Eur J Pharmacol. 1999 Aug 27;379(2-3):191-8. | ||||
Ref 534939 | Apparent efficacy of kappa-opioid receptor ligands on serum prolactin levels in rhesus monkeys. Eur J Pharmacol. 1999 Nov 3;383(3):305-9. | ||||
Ref 534953 | The antitussive activity of delta-opioid receptor stimulation in guinea pigs. J Pharmacol Exp Ther. 2000 Feb;292(2):803-9. | ||||
Ref 535113 | The selective kappa-opioid receptor agonist U50,488H attenuates voluntary ethanol intake in the rat. Behav Brain Res. 2001 May;120(2):137-46. | ||||
Ref 535539 | Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J Clin Gastroenterol. 2002 Jul;35(1 Suppl):S58-67. | ||||
Ref 535822 | NMR studies of an FK-506 analog, [U-13C]ascomycin, bound to FK-506-binding protein. J Med Chem. 1992 Jun 26;35(13):2467-73. | ||||
Ref 535870 | Kappa-opioid receptor selectivity for ischemic neuroprotection with BRL 52537 in rats. Anesth Analg. 2003 Dec;97(6):1776-83. | ||||
Ref 536122 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | ||||
Ref 536176 | Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol. 2006 Jan 25;6:3. | ||||
Ref 536224 | Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. | ||||
Ref 537853 | FK-506-binding protein: three-dimensional structure of the complex with the antagonist L-685,818. J Biol Chem. 1993 May 25;268(15):11335-9. | ||||
Ref 537931 | Beta-endorphin is a potent inhibitor of thymidine incorporation into DNA via mu- and kappa-opioid receptors in fetal rat brain cell aggregates in culture. J Neurochem. 1993 Feb;60(2):765-7. | ||||
Ref 538126 | The 12 kD FK 506 binding protein FKBP12 is released in the male reproductive tract and stimulates sperm motility. Mol Med. 1998 Aug;4(8):502-14. | ||||
Ref 543763 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 318). | ||||
Ref 544079 | Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development. AAPS J. 2009 June; 11(2): 312-322. | ||||
Ref 544320 | Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381. | ||||
Ref 550920 | US patent application no. 6,924,288, Enantiomerically pure opioid diarylmethylpiperzine and methods of using same. | ||||
Ref 551291 | Morphinan cyclic imines and pyrrolidines containing a constrained phenyl group: High affinity opioid agonists, Bioorg. Med. Chem. Lett. 5(24):2969-2974 (1995). | ||||
Ref 551379 | Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13. | ||||
Ref 551387 | [6-O-methyl-11C]Diprenorphine, Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. 2006 May 24 [updated 2007 May 12]. | ||||
Ref 551402 | Subramanian G, Paterlini MG, Portoghese PS, Ferguson DM: Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. J Med Chem. 2000 Feb 10;43(3):381-91. | ||||
Ref 551406 | Wax PM, Becker CE, Curry SC: Unexpected “gas” casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.